Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen, Inc. | 0.56% | 297.20 | 1.4% | $596.31m | |
| AMGN | Amgen, Inc. | 0.44% | 233.84 | 1.3% | $498.51m | |
| GILD | Gilead Sciences, Inc. | 0.22% | 67.08 | 1.0% | $356.60m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.56% | 367.67 | 2.6% | $292.07m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.41% | 220.27 | 1.9% | $272.17m | |
| ILMN | Illumina, Inc. | 0.11% | 326.94 | 3.5% | $235.54m | |
| CLVS | Clovis Oncology, Inc. | 12.98% | 12.10 | 14.7% | $219.20m | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 4.56% | 70.86 | 11.5% | $213.63m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.14% | 111.20 | 2.0% | $196.66m | |
| EXAS | EXACT Sciences Corp. | 1.32% | 85.30 | 24.0% | $166.59m | |
| A | Agilent Technologies, Inc. | 1.61% | 82.93 | 1.6% | $155.82m | |
| GBT | Global Blood Therapeutics, Inc. | 1.12% | 75.95 | 6.0% | $134.81m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.40% | 106.17 | 14.6% | $133.20m | |
| BOLD | Audentes Therapeutics, Inc. | 0.32% | 59.51 | 1.4% | $132.22m | |
| BLUE | bluebird bio, Inc. | 11.87% | 85.69 | 14.2% | $130.86m |
Company Profile
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.